<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 0R 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 26, 1996
----------------
CENTOCOR, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Pennsylvania 0-11103 23-2117202
- --------------------------------------------------------------------------------
(State or other juris- (Commission file (IRS Employer
diction of incorporation) number) Identification No.)
200 Great Valley Parkway, Malvern, Pennsylvania 19355
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (215) 651-6000
--------------
Not applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
------------
On January 26, 1996, the Registrant announced that the United States
Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee
had reviewed the safety and efficacy of the Registrant's product Myoscint/(R)/,
and had recommended approval for imaging in the setting of chest pain, suspected
to be caused by myocardial infarction. Myoscint is a monoclonal antibody which
reacts to heavy chain myosin following myocardial cell death. A copy of the
Registrant's press release for the announcement is filed as an exhibit to this
Current Report on Form 8-K.
Item 7. Financial Statements and Exhibits.
---------------------------------
Exhibits:
--------
99.1 Registrant's Press Release dated January 26, 1996.
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CENTOCOR, INC.
Registrant
Dated: January 30, 1996 By: /s/ George D. Hobbs
---------------------------------
George D. Hobbs, Vice President,
Corporate Counsel and
Secretary
<PAGE>
[LOGO OF CENTOCOR TO APPEAR HERE] PRESS RELEASE
________________________________________________________________________________
FOR IMMEDIATE RELEASE INVESTOR CONTACTS: MADELINE HOPKINS
(610) 651-6122
PAUL WULFING
(610) 889-4422
MEDIA CONTACT: BRUCE CARROLL
(610) 651-6214
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL
FOR CENTOCOR'S MYOSCINT/(R)/
MALVERN, PA, January 26, 1996 -- Centocor, Inc. (Nasdaq: CNTO) announced today
that the Food and Drug Administration, Cardiovascular and Renal Drugs Advisory
Committee has reviewed the safety and efficacy of Myoscint/(R)/, and has
recommended approval for imaging in the setting of chest pain, suspected to be
caused by myocardial infarction.
"We are extremely pleased with this recommendation from the Committee. It is
further confirmation of Centocor's regulatory capability," said David P.
Holveck, president and chief executive officer of Centocor, Inc. "With this
recommendation of Myoscint, Centocor continues to build on its success in
researching and developing new and innovative biotechnology products. Myoscint,
if approved for marketing in the U.S., compliments our profitable Diagnostics
Division."
Myoscint is a monoclonal antibody which reacts to heavy chain myosin following
myocardial cell death.
Myoscint has received marketing approval in several European countries, where
Mallinckrodt Medical, Inc. holds marketing rights to Myoscint. Currently,
Myoscint sales in Europe are not significant. A product license application is
also under review in Japan.
Centocor is a biotechnology company that develops therapeutic and diagnostic
human health care products for cardiovascular, autoimmune and infectious
diseases, and cancer. The company concentrates on research and development,
manufacturing and market development, with a primary technological focus on
monoclonal antibodies, with additional programs in gene vaccines and peptides.
